U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07303621) titled 'Population Pharmacokinetics of Elexacaftor-tezacaftor-ivacaftor in a Paediatric Population' on Nov. 19.
Brief Summary: Cystic fibrosis is a rare, progressive genetic disease caused by a mutation in the CFTR (cystic fibrosis transmembrane conductance regulator) gene. Respiratory and nutritional effects are crucial to patients' prognosis. Since the early years of 2010, etiological treatment has been based on the use of CFTRm (CFTR modulator), which aim to restore the function of the mutated protein. Initially used as monotherapy and targeting a limited number of patients, CFTRm has gradually been extended to a larger number of patient...